ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

elismetrep

Also written as “MT-8554”, “Elismetrep” and “MT-8554 low dose”.

Its studies are mostly in Migraine Disorders · Hot Flashes, led by 2 companies.

Drug pageElismetrep: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 29, 201714 company-led studies, 3 open or runningNext primary completion: Feb 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tanabe Pharmaits history only100 open or runningphase 2since May 29, 2017Apr 16, 2015none ahead
TriGemX Bio43 open or runningphase 3since Jun 9, 2026Feb 21, 2025Feb 2027phase 3 · NCT07645924

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of TriGemX Bio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2017Named elismetrepINNProposed as its International Nonproprietary Name in WHO's List 118 · before, MT-8554
  2. Feb 21, 2025First study: phase 2 study in Migraine DisordersFirst studyNCT06848075 · 431 enrolled · United States
  3. Jun 9, 20262 phase 3 studiesPhase 3 reachedNCT07645924, NCT07674654
  4. Sep 7, 2026Phase 3 study in Migraine DisordersNCT07816367 · 1,500 planned · United States

Ahead

  1. Feb 2027Primary completion: phase 3 study in Migraine DisordersNCT07645924
  2. Oct 2027Primary completion: phase 3 study in Migraine DisordersNCT07816367
  3. Jun 2028Primary completion: phase 3 study in Acute MigraineNCT07674654

TargetBeta

TRPM8 →read by rule
“Transient receptor potential cation channel subfamily M member 8 inhibitor”ChEMBL 37, by rule

Studies

All 4 TriGemX Bio leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07816367Migraine Disorders · United States3RecruitingOct 20271,500
NCT07674654Acute Migraine · United States3RecruitingJun 20281,000
NCT07645924Migraine Disorders · United States3RecruitingFeb 20271,800
NCT06848075Migraine Disorders · United States2CompletedAug 4, 2025431

How it is read

Names in the registry

  • “MT-8554”, 4 entries
  • “Elismetrep”, 3 entries
  • “MT-8554 low dose”, 3 entries
  • “MT-8554 high dose”, 3 entries
  • “MT-8554 middle dose”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.